Niraparib

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Organization(s)	Biomarker(s)	Cancer type	Therapy(ies)
FDA (1)	BRCA1 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisone
FDA (1)	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisone
FDA (1)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisone
FDA (1)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisone
FDA (1)	BRCA1 pathogenic variants	Ovarian Epithelial Tumor	Niraparib
FDA (1)	BRCA2 pathogenic variants	Ovarian Epithelial Tumor	Niraparib
FDA (1)	BRCA1 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Niraparib
FDA (1)	BRCA2 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Niraparib
FDA (1)	BRCA1 pathogenic variants	Peritoneal Serous Carcinoma	Niraparib
FDA (1)	BRCA2 pathogenic variants	Peritoneal Serous Carcinoma	Niraparib
EMA (1)	BRCA1 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisolone
EMA (1)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisolone
EMA (1)	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisolone
EMA (1)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisolone